Compare PVH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | BEAM |
|---|---|---|
| Founded | 1881 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 1994 | 2019 |
| Metric | PVH | BEAM |
|---|---|---|
| Price | $79.73 | $32.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $90.53 | $50.75 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $8,950,200,000.00 | $24,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $1.86 | $33.77 |
| P/E Ratio | $41.77 | ★ N/A |
| Revenue Growth | 3.44 | ★ 33.33 |
| 52 Week Low | $59.60 | $15.60 |
| 52 Week High | $100.75 | $38.26 |
| Indicator | PVH | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 48.29 |
| Support Level | $76.41 | $23.83 |
| Resistance Level | $79.91 | $35.18 |
| Average True Range (ATR) | 3.09 | 2.84 |
| MACD | 0.76 | -0.06 |
| Stochastic Oscillator | 96.34 | 21.32 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.